Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

Abstract COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled phase 1 and phase 2 trials to assess the safety, tolerability and immunogenicity of a recombinant COVID-19 vaccine...

Full description

Bibliographic Details
Main Authors: Fan-Yue Meng, Fan Gao, Si-Yue Jia, Xiang-Hong Wu, Jing-Xin Li, Xi-Ling Guo, Jia-Lu Zhang, Bo-Pei Cui, Zhi-Ming Wu, Ming-Wei Wei, Zhi-Long Ma, Hai-Lin Peng, Hong-Xing Pan, Lin Fan, Jing Zhang, Jiu-Qin Wan, Zhong-Kui Zhu, Xue-Wen Wang, Feng-Cai Zhu
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-021-00692-3

Internet

https://doi.org/10.1038/s41392-021-00692-3

Similar Items